|Poll|April 15, 2014

Mini-quiz: Pharmacotherapy for Alcohol Dependence

What medications are FDA approved for alcohol dependence? Take the quiz and learn more.

Newsletter

Receive trusted psychiatric news, expert analysis, and clinical insights — subscribe today to support your practice and your patients.

Subscribe

Related Content

Building Trust in Schizophrenia Care: How the Therapeutic Alliance Shapes Outcomes

ByGerald A. Maguire, MD

July 11th 2026

Expanding ADHD Pharmacology: Pipeline Highlights With Ann Childress, MD

ByAnn Childress, MD

July 10th 2026

Emerging Neuromodulation and Pharmacotherapy for Treatment-Resistant Depression

ByCharles Debattista, MD

July 10th 2026

Podcast: How AI Can Help in Everyday Psychiatry. A Conversation With Roy Perlis, MD

ByJoseph F. Goldberg, MD,Roy Perlis, MD

July 10th 2026

Consensus Guidelines for IV Ketamine: Safe Clinical Practice

BySandhya Prashad, MD

July 9th 2026

Latest CME

In-Person Event

Southern California Psychiatry Conference

July 10-11, 2026

Register now!

Video

(CME Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Gus Alva, MD, DFAPA; Ilan Melnick, MD

Video

Clear Skin, Clear Mind: Integrating Mental Health into Psoriasis Care

John Koo, MD; T.J. Chao, MPAS, PA-C

Video

Expert Illustrations & Commentary: Visualizing the Role of Novel Muscarinic Agents in the Management of Schizophrenia

Ilan Melnick, MD; Linda Collado, MD, DABPN, FAPA; Maria Collado, MD, FAPA

Video

Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Patricia Junquera, MD; Maria Collado, MD; Erin C. Crown, MHSPAS, PA-C, Psych-CAQ

Video

Expert Illustrations & Commentary: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Juan D. Oms, MD, FAPA; Linda Collado, MD, DABPN, FAPA; Ginger Shupe, MD

Video

(CPE Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Gus Alva, MD, DFAPA; Ilan Melnick, MD

Video

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Jason Kellogg, MD; Gus Alva, MD, DFAPA; Melanie Barrett, MD; Yvette Elpidio, MSN, FNP-C

Mini-quiz: Pharmacotherapy for Alcohol Dependence

Related Content

Building Trust in Schizophrenia Care: How the Therapeutic Alliance Shapes Outcomes

Expanding ADHD Pharmacology: Pipeline Highlights With Ann Childress, MD

Emerging Neuromodulation and Pharmacotherapy for Treatment-Resistant Depression

Podcast: How AI Can Help in Everyday Psychiatry. A Conversation With Roy Perlis, MD

Consensus Guidelines for IV Ketamine: Safe Clinical Practice

Latest CME

Southern California Psychiatry Conference

(CME Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Clear Skin, Clear Mind: Integrating Mental Health into Psoriasis Care

Expert Illustrations & Commentary: Visualizing the Role of Novel Muscarinic Agents in the Management of Schizophrenia

Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Expert Illustrations & Commentary: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

(CPE Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Trending on Psychiatric Times

New 6-Month Data From Second Phase 3 Trial Confirms Rapid Effect of COMP360 for TRD

Filling the Gap Between IV Ketamine Clinical Use and Evidence-Based Standards

Developments in Cannabis Withdrawal and Addiction Treatment

Expanding ADHD Pharmacology: Pipeline Highlights With Ann Childress, MD

Emerging Neuromodulation and Pharmacotherapy for Treatment-Resistant Depression